Category: BÜHLMANN fCAL® ELISA RUO Applications Citations

All of the publications in this citation list describe applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.) thus the “non-diagnosis” citations below should be used for information only.

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal.  PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than
Continue Reading

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

BÜHLMANN fCAL® ELISA Citation Zhulina, Y. et al., 2016, The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease, Aliment Pharmacol Ther.  PMID: 27402063 DOI: 10.1111/apt.13731 Highlight from this Publication “Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD.“ Read Citation BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic
Continue Reading

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis

BÜHLMANN fCAL® ELISA: Kristensen, V., A. Roseth, et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.  Gastroenterology Research and Practice; Volume 2017 (2017), Article ID 2098293, 5 pages.  DOI: 10.1155/2017/2098293. Highlights from this Publication “Conclusions. Fecal calprotectin <250 μg/g after medical treatment for active ulcerative colitis is a reliable marker of endoscopic
Continue Reading

Diagnostic Accuracy of Fecal Calprotectin in Assessing the Severity of Inflammatory Bowel Disease: From Laboratory to Clinic

BÜHLMANN fCAL® ELISA: S. Moein, D. Quujeq et al. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017; 8(3):178-182 DOI: 10.22088/cjim.8.3.178. Highlights from this Publication “ The current study also suggested 78.4 µg/g as the cut-off level for FC by 100% sensitivity and
Continue Reading

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA: Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198 Highlights from this Publication “This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable
Continue Reading

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725.

Highlight from this Publication:

“Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.”
Continue Reading